ACCEL-LOADING-ACS Study

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether adjunctive cilostazol loading/maintenance to standard treatment (aspirin, clopidogrel, and statin) is effective in reduction of major adverse cardiovascular events, platelet activation, inflammation and myonecrosis in patients with non-ST-elevation acute coronary syndrome (ACS)undergoing percutaneous coronary intervention (PCI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gyeongsang National University Hospital
• Treatments: Cilostazol

Criteria

Inclusion Criteria:

• at least 18 years of age

• Non-ST-elevation ACS patients undergoing PCI within 48 hours after hospitalization

Exclusion Criteria:

• ST segment elevation acute myocardial infarction

• NSTE ACS with high-risk features warranting emergency coronary angiography

• Oral anticoagulation therapy with warfarin

• Use of pre-procedural glycoprotein IIb/IIIa inhibitor

• Contraindication to antiplatelet therapy

• AST or ALT ≥ 3 times upper normal

• Left ventricular ejection fraction < 30%

• WBC < 3,000/mm3, platelet < 100,000/mm3

• Creatinine ≥ 3 mg/dl

• stroke within 3 months